Results 261 to 270 of about 13,388,827 (299)

DPP-4 inhibitors: pharmacological differences and their clinical implications

Expert Opinion on Drug Safety, 2014
Recently, incretin-based therapy was introduced for the treatment of type 2 diabetes (T2D). In particular, dipeptidyl peptidase-4 inhibitors (DPP-4i) (sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin) play an increasing role in the management of T2D.An extensive literature search was performed to analyze the pharmacological ...
Ceriello A, SPORTIELLO, Liberata, RAFANIELLO, Concetta, ROSSI, Francesco   +3 more
openaire   +2 more sources

Wildagliptyna - wyjątkowy inhibitor DPP-4

Medycyna Faktów, 2022
Wildagliptyna jest jedynym lekiem z grupy inhibitorów DPP-4, który stosuje się 2 razy dziennie. Chociaż nie przeprowadzono badania poświęconego bezpieczeństwu sercowo-naczyniowemu stosowania tego leku, to licznie opublikowane metaanalizy oraz badania obserwacyjne jednoznacznie potwierdziły bezpieczeństwo wildagliptyny w tym zakresie.
openaire   +2 more sources

How safe are DPP‐4 inhibitors?

Practical Diabetes, 2013
AbstractAbstract.
Laura McCreight, Miles Fisher
openaire   +1 more source

DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control

Archives of Pharmacal Research, 2016
Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) are an emerging class of antidiabetic drugs that constitutes approximately fifty percent of the market share of the oral hypoglycemic drugs. Its mechanism of action for lowering blood glucose is essentially via inhibition of the rapid degradation of incretin hormones, such as glucagon-like peptide ...
openaire   +2 more sources

Inappropriate Use of DPP-4 Inhibitors

2014
Background: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a newer class of oral anti-hyperglycemic agents for the treatment of type 2 diabetes. They have shown reduction of blood glucose, but potential impact on cardiovascular outcomes and long-term safety remain inconclusive. For that reasons DPP-4[for full text, please go to the a.m. URL]
Reichel, A, Blank, S, Tamminga, M, Schoch, GG, Steimle, T   +4 more
openaire   +1 more source

[DPP-4 inhibitors in nephropatics].

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia
The use of glucose-lowering drugs in advanced stage diabetic nephropathic patients should be done very carefully. Some drugs are contraindicated or not recommended. The same insulin needs a dose reduction to avoid dangerous hypoglycemia. For some years the use of inhibitors of the DDP-4 has been approved in T2DM patients with CKD III and IV stage ...
Annamaria, Bruzzese, Maria, Pasquale, Carmela, Aloisi, Giuseppe, Costantino, Michele, Buemi   +4 more
openaire   +1 more source

DPP-4 Inhibitors

2017
T. Biftu, R. SinhaRoy
openaire   +1 more source

Synthesis of a DPP-4 Inhibitor

Synfacts, 2020
openaire   +1 more source

Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) – A systematic review, meta-analysis, and meta-regression

Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021
Michael Anthonius Lim, Arief Wibowo, Henny Juliastuti   +2 more
exaly  

Effect of Dipeptidyl Peptidase-IV (DPP-IV) Inhibitor (Vildagliptin) on Peripheral Nerves in Streptozotocin-induced Diabetic Rats

Archives of Medical Research, 2009
Tae Sun Park, Heung Yong Jin, Wei Jing Liu   +2 more
exaly